Biosimulation market seen reaching $14 billion by 2033

Persistence Market Research says the global biosimulation market will rise from $4.6 billion in 2026 to $14.0 billion by 2033, driven by pharmaceutical R&D, precision medicine and wider use of simulation-based drug development. North America leads now, while Asia Pacific is expected to grow fastest as digital tools and biotech investment expand.

Why it matters: - Biosimulation is becoming a core tool for drug discovery and development. - The technology helps companies predict biological responses, optimize clinical trials and reduce development costs. - Wider adoption could improve decision-making across pharmaceutical, biotechnology and medical device research.

What happened: - Persistence Market Research estimated the global biosimulation market at US$ 4.6 billion in 2026. - The firm projects the market will reach US$ 14.0 billion by 2033. - The forecast implies a 17.1% compound annual growth rate from 2026 to 2033. - The report was issued in Brenford, London, U.K., on July 22, 2026.

The details: - Software solutions remain the largest product segment because they are widely used for predictive modeling, simulation, visualization and data analysis. - Services are gaining traction as companies look for specialized support on complex simulation projects and regulatory submissions. - Pharmaceutical and biotechnology companies make up the largest end-user group. - Contract research organizations, academic research institutes and healthcare organizations are also expanding use of biosimulation. - North America leads the market on the back of strong research infrastructure, higher healthcare spending and a concentration of major pharmaceutical companies. - Europe is a significant market, supported by biotechnology research, academic-industry collaboration and favorable regulatory initiatives. - Asia Pacific is emerging as a fast-growing region because of expanding clinical research, improving healthcare infrastructure and higher biotech investment. - The report also points to model-informed drug development as a growing driver of clinical research efficiency.

Between the lines: - The growth forecast reflects a broader shift toward simulation-based drug development as regulators become more open to predictive approaches. - Demand is also tied to the push for precision medicine, where patient-specific modeling can improve therapy design and trial targeting. - Artificial intelligence, machine learning and cloud-based platforms are likely to widen access and improve scalability. - The market opportunity is strongest where drug development costs are high and research timelines are under pressure.

What's next: - Biosimulation adoption is likely to keep rising as pharmaceutical R&D expands and more companies seek to lower trial failure rates. - Emerging markets could gain share if healthcare infrastructure and biotech funding continue improving. - Continued regulatory acceptance will be important for faster use of simulation in development workflows. - The report identifies companies including Cadence Design Systems, Certara, Simulations Plus, Dassault Systèmes, Schrödinger, Advanced Chemistry Development, Physiomics, Genedata, InSilicoTrials Technologies and Chemical Computing Group.

The bottom line: - Biosimulation is moving from a specialized research tool to a mainstream part of drug development, with software and North America leading the market today and precision medicine helping drive the next leg of growth. - More information is available in the report sample, custom report requests and the full report.